USMCA Watch: Eli Lilly Exports Slip, Pfizer Dosed Up As Drug Rules Are Abandoned December 5, 2019 The administration of President Donald Trump may be willing to drop proposals related to standardized biologic drug patent lengths in order to secure passage of the U.S.-Mexico-Canada Agreement, USMCA, through the U.S. House of Representatives. Setting patent protections to 10 years across the... Read more →